Cellectar Biosciences Inc

NASDAQ:CLRB   2:18:04 PM EDT
0.64
-0.02 (-3.04%)
: $0.67 +0.03 (+3.91%)
Products, Regulatory

Cellectar’S Iopofosine I-131 Exhibits Signals Of Efficacy In Phase I Study For Pediatric Brain And Solid Tumors

Published: 11/16/2021 14:54 GMT
Cellectar Biosciences Inc (CLRB) - Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors.
Cellectar Biosciences - Based Upon Data We Will Continue to Enroll Patients With High Grade Gliomas and Soft Tissue Sarcomas.
Cellectar Biosciences Inc - Look Forward to Engaging With FDA in Order to Outline a Potential Registrational Pathway.